HC Wainwright Cuts Cardiff Oncology (NASDAQ:CRDF) Price Target to $13.00

Cardiff Oncology (NASDAQ:CRDF) had its price objective cut by HC Wainwright from $14.00 to $13.00 in a research report report published on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Craig Hallum assumed coverage on Cardiff Oncology in a research report on Friday, September 6th. They issued a “buy” rating and a $8.00 target price on the stock.

Cardiff Oncology Stock Performance

NASDAQ:CRDF opened at $3.46 on Friday. The stock has a 50 day moving average price of $2.76 and a 200 day moving average price of $2.75. The stock has a market cap of $161.06 million, a PE ratio of -3.68 and a beta of 1.93. Cardiff Oncology has a one year low of $0.97 and a one year high of $6.42.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Cardiff Oncology by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock valued at $10,260,000 after buying an additional 9,468 shares during the period. Assenagon Asset Management S.A. lifted its stake in Cardiff Oncology by 380.6% in the second quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock worth $2,699,000 after acquiring an additional 962,940 shares during the last quarter. MAI Capital Management grew its holdings in Cardiff Oncology by 0.7% during the 3rd quarter. MAI Capital Management now owns 663,363 shares of the company’s stock worth $1,771,000 after acquiring an additional 4,569 shares in the last quarter. Blair William & Co. IL increased its position in shares of Cardiff Oncology by 32.2% in the 2nd quarter. Blair William & Co. IL now owns 227,630 shares of the company’s stock valued at $505,000 after purchasing an additional 55,450 shares during the last quarter. Finally, GSA Capital Partners LLP raised its holdings in shares of Cardiff Oncology by 432.7% in the 3rd quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock valued at $498,000 after purchasing an additional 151,613 shares in the last quarter. Hedge funds and other institutional investors own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.